Navigation Links
Personalized Medicine Makes Significant Headway Following the Rapid Evolution of U.S. Molecular Diagnostics Market, Finds Frost & Sullivan
Date:5/5/2009

MOUNTAIN VIEW, Calif., May 5 /PRNewswire/ -- As early diagnosis of cancer is critical for faster cure, longer survival, and better quality of life for patients, better access to diagnostics is the uppermost priority for primary care. Innovative molecular technologies have generated a wave of cancer diagnostics developed by dynamic new market entrants. These efforts will go a long way in addressing the unmet needs in the early diagnosis of cancer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

Biomarker development is a major area of focus of the FDA-driven Critical Path Initiative. The biomarker development initiative will streamline the clinical trials process and ensure the development of diagnostics, targeted therapeutics, and relevant dosage regimens. Recent changes initiated by the European Medicines Agency (EMEA) in Europe are expected to have a spillover effect on the U.S. cancer molecular diagnostics (CMD) market and fuel growth in the companion diagnostics segment.

New analysis from Frost & Sullivan (http://www.drugdiscovery.frost.com), U.S. Cancer Molecular Diagnostics Markets, finds that this market earned revenues of over $270.1 million in 2007 and estimates this to reach $1.83 billion by 2014.

If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table of contents, please send an e-mail to Christina Alfaro, Corporate Communications, at christina.alfaro@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country.

"The development of companion diagnostics is a game-changing phenomenon, which will impact the structure and dynamics of the pharmaceutical and biotechnology industry in the near future," advises Frost & Sullivan Senior Analyst Dr. Sudeep Basu. "Companion diagnostics will drive M&A activity and strategic partnerships in this market, in addition to encouraging a systems biology approach in attacking pathways as opposed to single targets."

The National Institute of Health-National Cancer Institute (NIH-NCI) programs, the FDA's Critical Path Initiative, and the availability of advanced tools have also speeded up market momentum. The Oncology Biomarkers Qualification Initiative (OBQI) program marshals public and private support to collaborate and develop the new rules of the game.

Considering the obvious benefits offered by this method and the lack of any deleterious effect observed with the testing, the likelihood of FDA granting approval for this method is high.

The flux in the regulatory environment surrounding the U.S. CMD market poses a major challenge to companies operating in this domain. Frequent adjustments to changing time lines and interim guidelines have proved to be an impediment for new entrants attempting to introduce novel tests to market.

"While FDA approval is no guarantee of market success, it surely helps the process," adds Dr. Basu. "FDA approval is based on a host of factors, and importantly, is an approval of the high levels of clinical relevance of the test, and low levels of risk which stems from the significant clinical studies carried out by the company for validating the diagnostic assay."

Besides adjusting to the ever-changing regulatory environment, participants must skillfully navigate the reimbursement space to ensure that growth continues on an upward trajectory.

A dual-pronged strategy -- bringing products to market through the Clinical Laboratory Improvement Amendments (CLIA) route and gaining early market dominance as well as going through the FDA process -- must be devised to tackle the regulatory and reimbursement barriers and achieve the speedy commercialization of molecular diagnostic tests.

This two-pronged approach will promote overall market visibility. It also ratchets up the awareness quotient among physicians. This serves to increase the overall branding and visibility of the test in the market. In order to interact smoothly with reimbursement agencies and convince them, U.S. CMD companies must accomplish insightful pharmacoeconomic analysis to display the value proposition of CMD.

U.S. Cancer Molecular Diagnostics Markets is part of the Drug Discovery and Clinical Diagnostics Growth Partnership Service program, which also includes research in the following markets: U.S. molecular diagnostics markets for emerging infectious disease tests, U.S. flow cytometry markets, and U.S. reference laboratory markets. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

U.S. Cancer Molecular Diagnostics Markets

N39E

    Contact:
    Christina Alfaro
    Corporate Communications - North America
    P: 210.247.3830
    F: 210.348.1003
    E: christina.alfaro@frost.com

   http://www.frost.com/


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Biodesix Advances the Field of Personalized Medicine With the Launch of VeriStrat(R)
2. Personalized Medicine for Mental Illness on the Horizon
3. Mayo Clinic and Microsoft Deliver a Powerful and Personalized Consumer Solution for Managing Health
4. Ocean Cosmetic Medicine of Santa Monica Has Created Something New: Personalized Boutique Style Aesthetic Treatments
5. Frost & Sullivan Recognizes CRi for Innovations Leading to Personalized Medicine
6. Chicago-area ASBS Bariatric Surgery Center of Excellence Provides Personalized Care Like No Other Weight-Loss Surgery Program
7. Personalized genome sequencing reveals coding error in gene for inherited pancreatic cancer
8. Adena Shoulder Surgeon Blends Innovative Techniques with Personalized Patient Care
9. Investing in personalized medicine will benefit Canada
10. UCLA scientists develop crystal ball for personalized cancer treatment
11. One Million Americans Now Receive Personalized FDA Drug Safety Alerts Through iGuard.org
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... , ... March 23, 2017 - Crawford Technologies announced today ... invoices, bills, statements and other correspondence when they have been lost or destroyed. ... print the documents and batch them for efficient handling. , Many organizations ...
(Date:3/23/2017)... ... March 23, 2017 , ... ChenMed, a privately ... completion of the strategic executive team expansion needed to further optimize growth and ... executive team,” says Christopher Chen, MD, ChenMed Chief Executive Officer. “George Wheeler ...
(Date:3/23/2017)... ... ... It’s that time of year again! Time to think about summer plans ... which can be frustrating when they don’t even know how to begin describing their ... relations firm outside of Philadelphia, have offered these three tips to make the search ...
(Date:3/23/2017)... ... March 23, 2017 , ... The ... Americans facing life-altering and fatal diseases in opposition to the President’s Fiscal ... would eviscerate care, services, and hope for the most vulnerable among us. , ...
(Date:3/23/2017)... ... March 23, 2017 , ... The Boulevard is honored to ... All events will be located in the Main West Entrance of The Boulevard ... ID event. No appointment is necessary and each child with a parent or guardian ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... Global Colposcope Market by Manufacturers, Countries, Type and Application, ... especially in North America , Europe ... America , Middle East and ... manufacturers, regions, type and application. ... Browse 190 Tables and Figures, 19 Major Company Profiles, ...
(Date:3/23/2017)... , Mar 23, 2017 NeuroVive ... company, today announced that the English version of the Annual ... www.neurovive.com .  ... About NeuroVive NeuroVive Pharmaceutical AB is ... the discovery and development of medicines that preserve mitochondrial integrity ...
(Date:3/22/2017)... March 22, 2017  DarioHealth Corp. (NASDAQ: DRIO), ... health and big data solutions, today reported financial ... month period ended December 31, 2016. ... $2.8 million, increased 241% compared to the full ... growth throughout the entire year  ...
Breaking Medicine Technology: